Clinical trials: Ocular Hypertension Glaucoma
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
Patient Preference Comparison of AZARGA Versus COSOPT
The purpose of this study was to assess patient preference regarding ocular comfort of AZARGA® compared to COSOPT® after one week instillation of each study medication.
- Trial name
- NCT01340014
- Testing
- Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension, Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
- Volunteers
- 112 people
- Sponsor
- Alcon Research
Cataract, Ocular Hypertension
Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma
The goal of this clinical trial is to learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma.
- Conditions
- Cataract, Ocular Hypertension, Glaucoma
- Trial name
- NCT07154797
- Testing
- Bimatoprost Implant System / IOL Combination
- Where
- Honduras
- Volunteers
- 24 people
- Sponsor
- SpyGlass Pharma, Inc.
Glaucoma
Ocular Hypotensive Efficacy of AR-102
A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure.
- Trial name
- NCT00523250
- Testing
- AR-102 0.003% Ophthalmic Solution, AR-102 0.005% Ophthalmic Solution, AR-102 0.01% Ophthalmic Solution
- Where
- 8 sites in United States
- Volunteers
- 82 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma (OAG)
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial
- Trial name
- NCT07220876
- Testing
- VisiPlate Glaucoma Implant
- Where
- 14 sites in United States, South Africa
- Volunteers
- 165 people
- Sponsor
- Avisi Technologies Inc.
Glaucoma, Open-Angle
Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma
The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.
- Trial name
- SAFARI FU (NCT05159817)
- Where
- Armenia
- Volunteers
- 19 people
- Sponsor
- Ciliatech
Open Angle Glaucoma, Primary Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- FRONTIER (NCT05198297)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alcon Research
Healthy Eyes, Eye Diseases
Triton Agreement and Precision Study
To Compare the agreement and precision between the Topcon DRI OCT Triton and the 3D OCT-1 Maestro with RDB.
- Trial name
- NCT03080714
- Testing
- Topcon DRI OCT Triton (plus), 3D OCT-1 Maestro
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.
Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative
Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.
The objective of this study is to demonstrate the ability of the Hydrus Implant to lower intraocular pressure in glaucoma patients undergoing cataract surgery.
- Conditions
- Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative, Cataract Unilateral Pending Extraction
- Trial name
- Hydrus II (NCT01818115)
- Testing
- Hydrus Implant, IOL placement
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 100 people
- Sponsor
- Ivantis, Inc.
Primary Open-angle Glaucoma, Primary Angle-Closure Glaucoma
Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
This is a prospective, multi-centre, cross sectional observational study to determine the prevalence of ocular surface disease (OSD) in glaucoma patients, nationwide.
- Conditions
- Primary Open-angle Glaucoma, Primary Angle-Closure Glaucoma, Pseudoexfoliation Glaucoma, Pigment Dispersion Glaucoma
- Trial name
- NCT04609345
- Volunteers
- 400 people
- Sponsor
- Santen Pharma Malaysia Sdn Bhd
Glaucoma, Neovascular
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
- Trial name
- VEGA (NCT02396316)
- Testing
- Aflibercept (Eylea, BAY 86-5321)
- Where
- 19 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Bayer
Glaucoma
Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU)
The purpose of this study is to evaluate the effectiveness and the safety of the cyclocoagulation using High Intensity Focused Ulatrsound with the EYEOP1 device in glaucoma patients
- Trial name
- NCT01592955
- Testing
- EYEOP1
- Where
- 7 sites in Israel, Italy and 2 more
- Volunteers
- 84 people
- Sponsor
- EyeTechCare
Open-angle Glaucoma, Ocular Hypertension
Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32
The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after six weeks of treatment in Caucasian and Japanese subjects.
- Trial name
- NCT00047606
- Testing
- IOP Lowering Medications
- Volunteers
- 84 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
Subjects are dosed twice daily at 9AM and 9PM for 12 weeks. The primary efficacy variable is the mean change in Intraocular Pressure (IOP) from baseline to 12 weeks.
- Trial name
- NCT01111890
- Testing
- Azarga (brinzolamide 1% / timolol 0.5%), Cosopt (dorzolamide 2% / timolol 0.5%)
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach.
- Trial name
- NCT05411198
- Testing
- XEN45 (Glaucoma Gel Stent)
- Where
- 25 sites in United States, Australia
- Volunteers
- 74 people
- Sponsor
- AbbVie
Glaucoma, Ocular Hypertension
Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A ophthalmic solution with Ganfort® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once daily for 12 weeks in patients with glaucoma or…
- Trial name
- NCT01177098
- Testing
- bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 561 people
- Sponsor
- Allergan
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004.
- Trial name
- OLE2 (NCT02537015)
- Testing
- Bimatoprost
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma, Trabeculectomy
Ologen (OculusGen)-Glaucoma MMC Control in Pakistan
The purpose of this study is to compare the safety and effectiveness of the ologen (OculusGen) Biodegradable Collagen Matrix Implant and the MMC group in filtration surgery.
- Trial name
- NCT00472810
- Testing
- ologen collagen matrix in glaucoma filtering surgery, MMC in glaucoma filtering surgery
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Pro Top & Mediking Company Limited
Glaucoma, Ocular Hypertension
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the…
- Trial name
- NCT02140060
- Testing
- Dose Level A / Brinzolamide 1% ophthalmic suspension, Dose Level B / Brinzolamide 1% ophthalmic suspension, Dose Level C / Brinzolamide 1% ophthalmic suspension
- Volunteers
- 327 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma
A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to…
- Trial name
- CATALYST (NCT05564091)
- Testing
- Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery
- Where
- 4 sites in United States, Germany
- Volunteers
- 78 people
- Sponsor
- Nova Eye, Inc.